Literature DB >> 23756108

Clinical evaluation of microRNA expression profiling in non small cell lung cancer.

A Markou1, I Sourvinou1, P A Vorkas1, G M Yousef2, E Lianidou3.   

Abstract

Deregulation of miRNAs expression levels has been detected in many human tumor types, and recent studies have demonstrated the critical roles of miRNAs in cancer pathogenesis. Numerous recent studies have shown that miRNAs are rapidly released from tissues into the circulation in many pathological conditions. The high relative stability of miRNAs in biofluids such as plasma and serum, and the ability of miRNA expression profiles to accurately classify discrete tissue types and disease states have positioned miRNAs as promising non-invasive new tumor biomarkers. In this study, we used liquid bead array technology (Luminex) to profile the expression of 320 mature miRNAs in a pilot testing group of 19 matched fresh frozen cancerous and non-cancerous tissues from NSCLC patients. We further validated our results by RT-qPCR for differentially expressed miRNAs in an independent group of 40 matched fresh frozen tissues, 37 plasma samples from NSCLC patients and 28 healthy donors. We found that eight miRNAs (miR-21, miR-30d, miR-451, miR-10a, miR-30e-5p and miR-126*, miR-126, miR-145) were differentially expressed by three different statistical analysis approaches. Two of them (miR-10a and miR-30e-5p) are reported here for the first time. Bead-array results were further verified in an independent group of 40 matched fresh frozen tissues by RT-qPCR. According to RT-qPCR miR-21 was significantly up-regulated (P = 0.010), miR-126* (P = 0.002), miR-30d (P = 0.012), miR-30e-5p (P < 0.001) and miR-451 (P < 0.001) were down-regulated, while miR-10a was not differentiated (P = 0.732) in NSCLC tissues. However, in NSCLC plasma samples, only three of these miRNAs (miR-21, miR-10a, and miR-30e-5p) displayed differential expression when compared to plasma of healthy donors. High expression of miR-21 was associated with DFI and OS both in NSCLC tissues (P = 0.022 and P = 0.037) and plasma (P = 0.045 and P = 0.065), respectively. Moreover, we report for the first time that low expression of miR-10a in NSCLC plasma samples was associated with worse DFI (P = 0.050) and high expression of miR-30e-5p was found to be associated with shorter OS (P = 0.048). In conclusion, circulating miR-21, miR-10a and miR-30e-5p in plasma should be further evaluated as potential non-invasive biomarkers in NSCLC.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  AD; Circulating miRNAs; DFI; LNA; Liquid bead array; MicroRNAs; NSCLC; Non small cell lung cancer; OS; RT-qPCR; SCC; Tumor markers; adenocarcinoma; disease free interval; locked nucleic acid; miR-21; miRNAs; microRNAs; non small cell lung cancer; overall survival; quantitative reverse transcription PCR; squamous cell carcinoma

Mesh:

Substances:

Year:  2013        PMID: 23756108     DOI: 10.1016/j.lungcan.2013.05.007

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  86 in total

1.  Circulating miR-21-5p and miR-148a-3p as emerging non-invasive biomarkers in thymic epithelial tumors.

Authors:  Teresa Bellissimo; Emanuele Russo; Federica Ganci; Carmen Vico; Andrea Sacconi; Flavia Longo; Domenico Vitolo; Marco Anile; Daniele Disio; Mirella Marino; Giovanni Blandino; Federico Venuta; Francesco Fazi
Journal:  Cancer Biol Ther       Date:  2016       Impact factor: 4.742

Review 2.  Epigenetics of lung cancer.

Authors:  Scott M Langevin; Robert A Kratzke; Karl T Kelsey
Journal:  Transl Res       Date:  2014-03-12       Impact factor: 7.012

3.  MiR-451 suppresses cell proliferation and metastasis in A549 lung cancer cells.

Authors:  Pin Yin; Rui Peng; Huimin Peng; Li Yao; Yan Sun; Li Wen; Tianhui Wu; Ji Zhou; Zheng Zhang
Journal:  Mol Biotechnol       Date:  2015-01       Impact factor: 2.695

4.  Down-regulation of miR-489 contributes into NSCLC cell invasion through targeting SUZ12.

Authors:  Zongtao Xie; Liming Cai; Runsheng Li; Jinyu Zheng; Hongyan Wu; Xiaoqi Yang; Hu Li; Zhiqiang Wang
Journal:  Tumour Biol       Date:  2015-04-02

5.  Overexpression of LIMD2 promotes the progression of non-small cell lung cancer.

Authors:  Feifei Zhang; Shana Qin; Xiang Xiao; Yuefa Tan; Peng Hao; Yikai Xu
Journal:  Oncol Lett       Date:  2019-06-12       Impact factor: 2.967

6.  Identification of lymph node metastasis-related microRNAs in lung adenocarcinoma and analysis of the underlying mechanisms using a bioinformatics approach.

Authors:  Li Yan; Demin Jiao; Huizhen Hu; Jian Wang; Xiali Tang; Jun Chen; Qingyong Chen
Journal:  Exp Biol Med (Maywood)       Date:  2016-11-14

Review 7.  Specific miRNA Disease Biomarkers in Blood, Serum and Plasma: Challenges and Prospects.

Authors:  Christina Backes; Eckart Meese; Andreas Keller
Journal:  Mol Diagn Ther       Date:  2016-12       Impact factor: 4.074

8.  miR-33a inhibits cell proliferation and invasion by targeting CAND1 in lung cancer.

Authors:  M Kang; Y Li; Y Zhao; S He; J Shi
Journal:  Clin Transl Oncol       Date:  2017-09-04       Impact factor: 3.405

Review 9.  Overview upon miR-21 in lung cancer: focus on NSCLC.

Authors:  Cecilia Bica-Pop; Roxana Cojocneanu-Petric; Lorand Magdo; Lajos Raduly; Diana Gulei; Ioana Berindan-Neagoe
Journal:  Cell Mol Life Sci       Date:  2018-07-20       Impact factor: 9.261

Review 10.  MicroRNA as tools and therapeutics in lung cancer.

Authors:  Jennifer F Barger; S Patrick Nana-Sinkam
Journal:  Respir Med       Date:  2015-02-19       Impact factor: 3.415

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.